LSD1 Antibody (1B2E5)

Product Specs
ItemLSD1 Antibody (1B2E5) - BSA Free
CompanyNovus Biologicals, a Bio-Techne Brand
Price $429.00Supplier Page View Company Product Page
Catalog NumberNB100-1762
NCBI Gene AliasesAOF2, CPRF, BHC110, LSD1, KDM1
ImmunogenPurified recombinant fragment of human LSD1 (between amino acids 400-600) expressed in E. coli. [UniProt# O60341]
ApplicationsChemotaxis,IF/IHC,ELISA,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Simple Western,Chromatin Immunoprecipitation (ChIP),Knockdown Validated
ClonalityMonoclonal
Quantity0.1 mg (also 0.025 mg)
ReactivityHuman,Mouse,Primate
IsotypeIgG1
Clone1B2E5
Conjugate/TagUnconjugated
FormatPBS
HostMouse
TargetLSD1
NCBI Full Gene Namelysine demethylase 1A
PurityProtein A or G purified
Molecular Weight93 kDa
Research AreaDNA Repair, DNA replication Transcription Translation and Splicing, Epigenetics
Antibody TypePrimary Antibodies
StorageStore at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles
Concentration1.0 mg/ml

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Sizes Available: 0.1 mg (also 0.025 mg)

Add to Compare List

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: https://www.novusbio.com

(1) KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancerMolecular OncologyMarch 23, 2026Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, et al.with KDM7A primary antibody (#NBP1‐81382, 1 : 100 dilution; Novus biologicals, Canada) and KDM1A (#NB100‐1762, 1 : 1000 dilution; Novus biologicals, Canada) incubated for 1 h at room temperature. High‐resolution

(2) "Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors"Human pathologyJanuary 1, 0001"Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S, Tanaka S, Sonobe H, Schüle R, Buettner R, et al."

(3) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biologyCarcinogenesisJanuary 1, 0001"Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J."

(4) "Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer"Molecular carcinogenesisJanuary 1, 0001"Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, Mongan NP."

(5) "Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma"Human pathologyJanuary 1, 0001"Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H."

(6) Lysine-specific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1) synergistically repress proinflammatory cytokines and classical complement pathway componentsBiochemical and biophysical research communicationsJanuary 1, 0001"Janzer A, Lim S, Fronhoffs F, Niazy N, Buettner R, Kirfel J."

(7) "High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer"Urologic oncologyJanuary 1, 0001"Lobo J, Rodrigues Â, Antunes L, Graça I, Ramalho-Carvalho J, Vieira FQ, Martins AT, Oliveira J, Jerónimo C, Henrique R."

(8) PKCα-LSD1-NF-κB-Signaling Cascade Is Crucial for Epigenetic Control of the Inflammatory ResponseMolecular cellJanuary 1, 0001"Kim D, Nam HJ, Lee W, Yim HY, Ahn JY, Park SW, Shin HR, Yu R, Won KJ, Bae JS, et al."

(9) Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cellsInternational journal of cancerJanuary 1, 0001"Haydn T, Kehr S, Willmann D, Metzger E, Schüle R, Fulda S."

(10) The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastomaActa neuropathologica communicationsJanuary 1, 0001"Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, et al."Autostainer (Dako Cytomation, Glostrup, Denmark). The primary antibody against KDM1A was diluted 1:250 (Cat.# NB100-1762, Novus Biologicals, Littleton, CO, USA). Pajtler et al. Acta Neuropathologica Communications 2013,

(11) "Targeting lysine-specific demethylase 1 (KDM1A/LSD1) impairs colorectal cancer tumorigenesis by affecting cancer cells stemness, motility, and differentiation"Cell death discoveryJanuary 1, 0001"Antona A, Leo G, Favero F, Varalda M, Venetucci J, Faletti S, Todaro M, Mazzucco E, Soligo E, Saglietti C, et al."Vienna, Austria) appropriately set. The primary monoclonal antibody used was an anti-KDM1A antibody (NB100-1762; Novus Biologicals, LLC, USA) diluted 1:1500. The positivity assessment was performed blinded by an

(12) Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breastBMC clinical pathologyJanuary 1, 0001"Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R."

(13) The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancerMolecular oncologyJanuary 1, 0001"Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ, Mongan NP."Rights was strictly observed. 2.2. Source of antibodies The following antibodies were used: LSD1 (NB100-1762, Novus Biologicals); JMJD2A (NB100-57563, Novus Biologicals, Littleton, CO) and anti-β-Actin (SC-1616,

Be the First to Write a Review!